

## **Pfenex Inc**

### **CORTELLIS COMPANY DETAILED PIPELINE REPORT**

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 27-Apr-2015

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

### DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 11

    Phase 2 Clinical..... 12

    Discovery..... 15

[Return to Table of Contents](#)

# Pfenex Inc

## COMPANY OVERVIEW

<b>Company Name</b>	Pfenex Inc
<b>Parent Company Name</b>	Pfenex Inc
<b>Website</b>	http://www.pfenex.com/
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	17
<b>Number of Inactive Drugs</b>	3
<b>Number of Patents as Owner</b>	5
<b>Number of Patents as Third Party</b>	0
<b>Number of Deals</b>	17
<b>Key Indications</b>	Inflammatory disease,Neutropenia,Bacillus anthracis infection,Cancer,Growth hormone deficiency,Multiple sclerosis,Plasmodium falciparum infection,Age related macular degeneration,Metastatic breast cancer,Non-Hodgkin lymphoma,Plasmodium infection,Rheumatoid arthritis,Unidentified indication
<b>Key Target-based Actions</b>	Interferon beta ligand,GCSF receptor agonist,GCSF ligand,GP IIb IIIa antagonist,Growth hormone ligand,Interferon alpha 2 ligand modulator,Interferon receptor modulator,TNF alpha ligand inhibitor,TNF antagonist,VEGF-A ligand inhibitor
<b>Key Technologies</b>	Biological therapeutic,Protein recombinant,Biosimilar product,Parenteral formulation unspecified,Injectable formulation,Antibody fragment,PEGylated formulation,Subcutaneous formulation,Antigen,Infusion,Intravenous formulation,Monoclonal antibody humanized

## COMPANY PROFILE

### SUMMARY

Pfenex Inc, headquartered in San Diego, CA is a leading biotechnology company focused on recombinant protein expression for a broad range of applications including therapeutic proteins, vaccines, research, reagents and biosimilars.

### ACQUISITIONS AND SPINOFFS

In April 2013, Pfenex, established an unnamed joint venture with Strides Acrolab subsidiary, Agila Biotech, to develop biosimilar products at Agila's Malaysian manufacturing facility. In July 2014, Strides disclosed that R&D programs for the biosimilar products were on track but further delays were expected in the manufacturing facility setup in Malaysia.

### FINANCIAL

In April 2015, the company priced its follow-on public offering of 6 million shares of its common stock at \$15.50 per share. Of the 6 million shares being offered, 2,610,000 were being offered by Pfenex and the remaining 3,390,000 shares were being offered by existing stockholders. Pfenex would not receive any proceeds from the shares sold by existing stockholders. The underwriters were granted a 30-day option to buy up to an additional 0.75 million shares of common stock from certain existing stockholders.

In September 2014, the shares began trading on the Russell Microcap and the Russell Global Indices.

In June 2014, Pfenex planned an IPO of common stock; in July 2014, the company priced its IPO of 8,333,333 common stock shares at a price of \$6.00 per share to the public and at that time, the underwriters were granted a 30-day option to purchase up to 1,250,000 additional common stock shares at the same price. The shares had begun trading under the symbol "PFNX" on the NYSE MKT; later that month, the offering was closed.

[Return to Table of Contents](#)




# PRODUCT PORTFOLIO SUMMARY

## DRUGS

### Drugs by Indication

Active Drugs by Indication Chart



[Return to Table of Contents](#)


## Drugs by Indication Table

Indication	Active	Inactive	Total
Inflammatory disease	5	0	5
Infectious disease	4	1	5
Hematological disease	3	1	4
Neoplasm	3	1	4
Musculoskeletal disease	2	0	2
Immune disorder	2	0	2
Endocrine disease	2	0	2
Gynecology and obstetrics	1	0	1
Neurological disease	1	0	1
Ocular disease	1	0	1
Growth disorder	1	0	1
Metabolic disorder	1	0	1
Unidentified indication	1	0	1
Cardiovascular disease	0	1	1
Respiratory disease	0	1	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Discovery	16
No Development Reported	3

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	7	0	0	0	7
Drug - Funding	4	0	1	0	5
Drug - Development/Commercialization License	1	0	0	0	1
Drug - Manufacturing/Supply	0	0	3	0	3

## CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Ocular disease	1	2

[Return to Table of Contents](#)



## Trials by Phase

Phase	Ongoing	All
Phase 1	2	3

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	2	0	2
Endocrine disease	6	0	6
Gastrointestinal disease	4	0	4
Growth disorder	2	0	2
Hematological disease	2	0	2
Immune disorder	5	0	5
Musculoskeletal disease	1	0	1
Neoplasm	8	0	8
Genetic disorder	1	0	1
Metabolic disorder	3	0	3
Neurological disease	4	0	4
Respiratory disease	3	0	3
Infectious disease	13	0	13
Unidentified indication	2	0	2
Inflammatory disease	4	0	4
Gynecology and obstetrics	1	0	1
Dermatological disease	2	0	2

[Return to Table of Contents](#)



\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### PF-582

#### PF-582 SNAPSHOT

<b>Drug Name</b>	PF-582
<b>Key Synonyms</b>	ranibizumab
<b>Originator Company</b>	Pfenex Inc
<b>Active Companies</b>	Hospira Inc;Pfenex Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Age related macular degeneration
<b>Target-based Actions</b>	VEGF-A ligand inhibitor
<b>Other Actions</b>	Angiogenesis inhibitor;Ocular antineovascularisation agent
<b>Technologies</b>	Biosimilar product;Injectable formulation;Ophthalmic formulation;Biological therapeutic;Parenteral formulation unspecified;Protein recombinant;Monoclonal antibody humanized;Antibody fragment
<b>Last Change Date</b>	17-Mar-2015

#### PF-582 DEVELOPMENT PROFILE

#### SUMMARY

Pfenex, in collaboration with Hospira, is developing PF-582, a biosimilar version of humanized anti-VEGF-A mAb fragment ranibizumab, as an injectable formulation, for the potential treatment of age-related macular degeneration (AMD). In November 2013, a phase Ib/IIa study in AMD was initiated. In August 2014, a phase III trial was planned for mid-2015 ; in March 2015, phase III trial was expected to begin in 2016. In February 2013, the company was seeking to outlicense the biosimilar in Western markets.

#### PF-582 DEVELOPMENT STATUS

##### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Pfenex Inc	Age related macular degeneration	New Zealand	Phase 2 Clinical	30-Nov-2013
Hospira Inc	Age related macular degeneration	US	Discovery	10-Feb-2015
Pfenex Inc	Age related macular degeneration	US	Discovery	21-Jun-2012

[Return to Table of Contents](#)



## PF-582 DRUG NAMES

Names	Type
ranibizumab	INN, USAN
PF-582	Research Code
ranibizumab biosimilar (age related macular degeneration), Pfenex	
ranibizumab biosimilar, Pfenex	

## PF-582 CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Age related macular degeneration											
0	0	0	0	0	0	1	2	0	0	1	2

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	1	2	0	0	1	2

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0


[Return to Table of Contents](#)



PF-582 DEALS AND PATENTS

DEALS


Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Pfenex Inc	1	0	1	0	2
Hospira Inc	0	0	1	0	1
Paragon Bioservices Inc	1	0	0	0	1

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1
Drug - Manufacturing/Supply	1	0	1

## Px-533

### Px-533 SNAPSHOT

Drug Name	Px-533
Key Synonyms	
Originator Company	Pfenex Inc
Active Companies	National Institutes of Health;Science Applications International Corp;Pfenex Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Plasmodium falciparum infection
Target-based Actions	
Other Actions	Antiparasitic;Protein subunit vaccine
Technologies	Injectable formulation;Biological therapeutic;Parenteral formulation unspecified;Peptide
Last Change Date	17-Mar-2015

### Px-533 DEVELOPMENT PROFILE

#### SUMMARY

Pfenex in collaboration with NIH and SAIC is investigating Px-533, a Plasmodium falciparum antigen vaccine comprising recombinant circumsporozoite protein (CSP) antigens, using Pfenex's Expression technology which is a Pseudomonas fluorescens-based platform technology, as an injectable formulation, for the potential prevention or treatment of malaria,. In November 2011, the vaccine was listed as being in the preclinical development. By November 2013, preclinical studies had been completed. In March 2015, phase I trial was expected to begin in 2015. In November 2013, the company was seeking to outlicense the vaccine.

### Px-533 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
National Institutes of Health	Plasmodium falciparum infection	US	Discovery	26-Jan-2011
Pfenex Inc	Plasmodium falciparum infection	US	Discovery	26-Jan-2011
Science Applications International Corp	Plasmodium falciparum infection	US	Discovery	26-Jan-2011

[Return to Table of Contents](#)




Px-533 DRUG NAMES

Names	Type
Plasmodium falciparum antigen vaccine (malaria), Pfenex/SAIC	
recombinant circumsporozoite protein antigen vaccine (malaria), Pfenex/SAIC	
Plasmodium falciparum antigen (circumsporozoite protein, malaria), Pfenex	
Px-533	Research Code

Px-533 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Science Applications International Corp	1	0	1	0	2
Pfenex Inc	1	0	1	0	2
US Government	0	0	1	0	1
Ajinomoto Co Inc	1	0	0	0	1

[Return to Table of Contents](#)



Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Manufacturing/Supply	1	0	1
Drug - Funding	1	0	1
Drug - Development Services	1	0	1

[Return to Table of Contents](#)

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Pfenex Inc	1	0	1

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
Formulation	1

[Return to Table of Contents](#)

## GCSF biosimilar, Pfenex/Sun

### GCSF biosimilar, Pfenex/Sun SNAPSHOT

<b>Drug Name</b>	GCSF biosimilar, Pfenex/Sun
<b>Key Synonyms</b>	
<b>Originator Company</b>	Pfenex Inc
<b>Active Companies</b>	Pfenex Inc;Sun Pharmaceutical Industries Ltd
<b>Inactive Companies</b>	Ranbaxy Laboratories Ltd
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Neutropenia
<b>Target-based Actions</b>	GCSF ligand;GCSF receptor agonist
<b>Other Actions</b>	Hematopoietic stimulant;Neutrophil stimulator
<b>Technologies</b>	Biosimilar product;Biological therapeutic;Subcutaneous formulation;Intravenous formulation;Infusion;Protein recombinant
<b>Last Change Date</b>	26-Mar-2015

### GCSF biosimilar, Pfenex/Sun DEVELOPMENT PROFILE

#### SUMMARY

Pfenex, presumed to be in collaboration with Sun Pharmaceutical Industries following Sun's acquisition of Ranbaxy is investigating a biosimilar version of a recombinant methionyl, non-glycosylated form GCSF, for the potential treatment of neutropenia. In June 2012, the biosimilar was in preclinical development; in September 2013, development was ongoing. In July 2012, Pfenex was seeking to outlicense the biosimilar.

### GCSF biosimilar, Pfenex/Sun DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

<b>Company</b>	<b>Indication</b>	<b>Country</b>	<b>Development Status</b>	<b>Date</b>
Pfenex Inc	Neutropenia	US	Discovery	29-Mar-2010
Sun Pharmaceutical Industries Ltd	Neutropenia	India	Discovery	25-Mar-2015

[Return to Table of Contents](#)




GCSF biosimilar, Pfenex/Sun DRUG NAMES

Names	Type
G-CSF	
GCSF biosimilar, Pfenex/Sun	
granulocyte colony-stimulating factor	
GCSF biosimilar, Pfenex/Ranbaxy	

GCSF biosimilar, Pfenex/Sun DEALS AND PATENTS

DEALS

Deals by Parent Company Chart



Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Sun Pharmaceutical Industries Ltd	0	0	1	0	1
Pfenex Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Technology - Other Proprietary	1	0	1

[Return to Table of Contents](#)

## Px-563L

### Px-563L SNAPSHOT

Drug Name	Px-563L
Key Synonyms	
Originator Company	Pfenex Inc
Active Companies	Pfenex Inc;US Health and Human Services Department
Inactive Companies	
Highest Status	Discovery
Active Indications	Bacillus anthracis infection
Target-based Actions	
Other Actions	Recombinant bacterial vector vaccine;Antibacterial
Technologies	Injectable formulation;Biological therapeutic;Parenteral formulation unspecified;Quick release formulation;Antigen
Last Change Date	17-Mar-2015

### Px-563L DEVELOPMENT PROFILE

#### SUMMARY

Pfenex, in collaboration with BARDA, is investigating Px-563L, a stable, fast acting, dose sparing vaccine containing an anthrax antigen, mutant recombinant protective antigen (mrPA) formulated in Immunovaccine's DepoVax liposome delivery platform, as a single dose vaccine, using Pfenex's Expression technology, which is a Pseudomonas fluorescens-based platform technology, as an injectable formulation, for the potential prevention or treatment of anthrax infection,.. In September 2013, the vaccine was listed as being in preclinical development. In April 2014, positive data were reported. In December 2014, an IND was filed ; in March 2015, a phase I trial was expected to begin in 2015.

### Px-563L DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Pfenex Inc	Bacillus anthracis infection	US	Discovery	03-Aug-2010
US Health and Human Services Department	Bacillus anthracis infection	US	Discovery	03-Aug-2010

[Return to Table of Contents](#)




Px-563L DRUG NAMES

Names	Type
mrPA vaccine (DepoVax, anthrax), Pfenex	
recombinant protective antigen vaccine (anthrax infection), Pfenex/BARDA	
Px-563L	Research Code
rPA vaccine (anthrax), Pfenex/BARDA	

Px-563L DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Pfenex Inc	2	0	1	0	3
US Government	0	0	2	0	2
Paragon Bioservices Inc	1	0	0	0	1

[Return to Table of Contents](#)



Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	2	0	2
Drug - Manufacturing/Supply	1	0	1

[Return to Table of Contents](#)

## interferon beta-1b biosimilar, Pfenex

### interferon beta-1b biosimilar, Pfenex SNAPSHOT

<b>Drug Name</b>	interferon beta-1b biosimilar, Pfenex
<b>Key Synonyms</b>	interferon beta-1b
<b>Originator Company</b>	Pfenex Inc
<b>Active Companies</b>	Pfenex Inc
<b>Inactive Companies</b>	Pfenex/Stelis Joint Venture
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Multiple sclerosis
<b>Target-based Actions</b>	Interferon receptor modulator;Interferon beta ligand
<b>Other Actions</b>	Immunomodulator
<b>Technologies</b>	Biosimilar product;Biological therapeutic;Subcutaneous formulation;Protein recombinant
<b>Last Change Date</b>	18-Mar-2015

### interferon beta-1b biosimilar, Pfenex DEVELOPMENT PROFILE

#### SUMMARY

Pfenex (following the removal of program from Joint Development and License Agreement) is investigating PF-530, a biosimilar version of Betaseron, an IFN beta-1b, for the potential treatment of multiple sclerosis,. In February 2015, a phase I trial was planned to be initiated in Australia. At that time, the first patient was expected to be enrolled in April 2015. In March 2015, a phase I trial was expected to begin in the first quarter of 2015, and data were expected in the second half of 2015.

Pfenex/Stelis (following Agila's name change), an unnamed joint venture created by Pfenex and Stelis (formerly Agila Biotech (Agila Specialties)), was previously investigating PF-530, for the potential treatment of multiple sclerosis,. However, in March 2015, the program was removed from the Joint Development and License Agreement.

### interferon beta-1b biosimilar, Pfenex DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Pfenex Inc	Multiple sclerosis	Australia	Discovery	23-Feb-2015
Pfenex Inc	Multiple sclerosis	US	Discovery	21-Jun-2012
Pfenex/Stelis Joint Venture	Multiple sclerosis	Malaysia	Discontinued	16-Mar-2015

[Return to Table of Contents](#)



interferon beta-1b biosimilar, Pfenex DRUG NAMES

Names	Type
interferon beta-1b biosimilar, Pfenex	
interferon beta-1b biosimilar, Pfenex/Stelis Joint Venture	
interferon beta-1b	BANN, INN, USAN
interferon beta-1b biosimilar, Pfenex/Agila Joint Venture	
PF-530	Research Code

interferon beta-1b biosimilar, Pfenex CLINICAL TRIALS

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	1	1	0	0	1	1

## somatropin biosimilar, Pfenex/Sun

### somatropin biosimilar, Pfenex/Sun SNAPSHOT

Drug Name	somatropin biosimilar, Pfenex/Sun
Key Synonyms	somatropin
Originator Company	Pfenex Inc
Active Companies	Pfenex Inc;Sun Pharmaceutical Industries Ltd
Inactive Companies	Ranbaxy Laboratories Ltd
Highest Status	Discovery
Active Indications	Growth hormone deficiency
Target-based Actions	Growth hormone ligand
Other Actions	
Technologies	Biological therapeutic;Parenteral formulation unspecified;Protein recombinant;Biosimilar product
Last Change Date	26-Mar-2015

### somatropin biosimilar, Pfenex/Sun DEVELOPMENT PROFILE

#### SUMMARY

Pfenex, presumed to be in collaboration with Sun Pharmaceutical Industries following Sun's acquisition of Ranbaxy is investigating a biosimilar version of the human growth hormone (HGH) ligand somatropin, presumably for the potential treatment of growth disorder. In September 2013, development was ongoing. In July 2012, the company was seeking to outlicense the biosimilar.

### somatropin biosimilar, Pfenex/Sun DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Pfenex Inc	Growth hormone deficiency	US	Discovery	29-Mar-2010
Sun Pharmaceutical Industries Ltd	Growth hormone deficiency	India	Discovery	25-Mar-2015

[Return to Table of Contents](#)




somatropin biosimilar, Pfenex/Sun DRUG NAMES

Names	Type
somatropin biosimilar, Pfenex/Sun	
somatropin biosimilar, Pfenex/Ranbaxy	
somatropin	USAN, BAN, INN
human growth hormone biosimilar, Pfenex/Sun	
human growth hormone biosimilar, Pfenex/Ranbaxy	

somatropin biosimilar, Pfenex/Sun DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Sun Pharmaceutical Industries Ltd	0	0	1	0	1
Pfenex Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Technology - Other Proprietary	1	0	1

[Return to Table of Contents](#)

## pegfilgrastim biosimilar, Pfenex

### pegfilgrastim biosimilar, Pfenex SNAPSHOT

Drug Name	pegfilgrastim biosimilar, Pfenex
Key Synonyms	pegfilgrastim
Originator Company	Pfenex Inc
Active Companies	Pfenex Inc
Inactive Companies	Pfenex/Stelis Joint Venture
Highest Status	Discovery
Active Indications	Neutropenia
Target-based Actions	GCSF receptor agonist
Other Actions	Neutrophil stimulator;Hematopoietic stimulant
Technologies	Biosimilar product;PEGylated formulation;Biological therapeutic;Subcutaneous formulation;Protein recombinant
Last Change Date	17-Mar-2015

### pegfilgrastim biosimilar, Pfenex DEVELOPMENT PROFILE

#### SUMMARY

Pfenex (following the removal of program from Joint Development and License Agreement) is investigating PF-529, a biosimilar version of pegfilgrastim, a PEGylated GM-CSF ligand, for the potential treatment of neutropenia,. In June 2012, the biosimilar was in preclinical development. In March 2015, development was ongoing. In June 2012, Pfenex was seeking to outlicense the biosimilar.

Pfenex/Stelis Joint Venture, an unnamed joint venture created by Pfenex and Stelis, was previously investigating a biosimilar version of pegfilgrastim, a PEGylated GM-CSF ligand, for the potential treatment of neutropenia,. However, in March 2015, the program was removed from the Joint Development and License Agreement.

### pegfilgrastim biosimilar, Pfenex DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Pfenex Inc	Neutropenia	US	Discovery	29-Mar-2010
Pfenex/Stelis Joint Venture	Neutropenia	Malaysia	Discontinued	16-Mar-2015

[Return to Table of Contents](#)




pegfilgrastim biosimilar, Pfenex DRUG NAMES

Names	Type
pegfilgrastim biosimilar, Pfenex	
pegfilgrastim	BANN, INN, USAN
PF-529	Research Code

pegfilgrastim biosimilar, Pfenex DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Sun Pharmaceutical Industries Ltd	0	0	1	0	1
Pfenex Inc	1	0	0	0	1

[Return to Table of Contents](#)



Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Technology - Other Proprietary	1	0	1

[Return to Table of Contents](#)

## undisclosed humanized VmAb biosimilar (metastatic breast cancer), Pfenex/Stelis

### undisclosed humanized VmAb biosimilar (metastatic breast cancer), Pfenex/Stelis SNAPSHOT

<b>Drug Name</b>	undisclosed humanized VmAb biosimilar (metastatic breast cancer), Pfenex/Stelis
<b>Key Synonyms</b>	
<b>Originator Company</b>	Inbiopro Solutions Pvt Ltd
<b>Active Companies</b>	Pfenex/Stelis Joint Venture
<b>Inactive Companies</b>	Inbiopro Solutions Pvt Ltd;Stelis Biopharma Pvt Ltd
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Metastatic breast cancer
<b>Target-based Actions</b>	ErbB2 tyrosine kinase receptor inhibitor
<b>Other Actions</b>	Anticancer monoclonal antibody
<b>Technologies</b>	Biosimilar product;Biological therapeutic;Parenteral formulation unspecified;Protein recombinant;Monoclonal antibody humanized
<b>Last Change Date</b>	20-Sep-2014

### undisclosed humanized VmAb biosimilar (metastatic breast cancer), Pfenex/Stelis DEVELOPMENT PROFILE

#### SUMMARY

Pfenex/Stelis (following Agila's name change), an unnamed joint venture created by Pfenex and Stelis (formerly Agila Biotech (Agila Specialties)), following the acquisition of Inbiopro, is investigating an angiogenesis inhibitor and Her-2/neu receptor expression down-regulator, IBPM-003TZ, a humanized anti-VmAb and a biosimilar version of an undisclosed drug, for the potential treatment of metastatic breast cancer „. In 2011, process development and toxicology studies had begun ; in January 2014, IBPM-003TZ was listed on the Inbiopro company's pipeline.

### undisclosed humanized VmAb biosimilar (metastatic breast cancer), Pfenex/Stelis DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Pfenex/Stelis Joint Venture	Metastatic breast cancer	India	Discovery	16-Apr-2013
Inbiopro Solutions Pvt Ltd	Metastatic breast cancer	India	Discontinued	09-Dec-2010

[Return to Table of Contents](#)



undisclosed humanized VmAb biosimilar (metastatic breast cancer), Pfenex/Stelis DRUG NAMES

Names	Type
undisclosed humanized VmAb biosimilar (metastatic breast cancer), Pfenex/Stelis	
undisclosed humanized VmAb biosimilar (metastatic breast cancer), Inbiopro	
IBPM-003TZ	Research Code
undisclosed humanized VmAb biosimilar (metastatic breast cancer), Stelis	
undisclosed humanized VmAb biosimilar (metastatic breast cancer), Agila	

[Return to Table of Contents](#)

## undisclosed mAb biosimilar (cancer), Pfenex/Stelis

### undisclosed mAb biosimilar (cancer), Pfenex/Stelis SNAPSHOT

Drug Name	undisclosed mAb biosimilar (cancer), Pfenex/Stelis
Key Synonyms	
Originator Company	Inbiopro Solutions Pvt Ltd
Active Companies	Pfenex/Stelis Joint Venture
Inactive Companies	Inbiopro Solutions Pvt Ltd;Stelis Biopharma Pvt Ltd
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	ErbB2 tyrosine kinase receptor inhibitor
Other Actions	Anticancer monoclonal antibody;Anticancer protein kinase inhibitor
Technologies	Biosimilar product;Biological therapeutic;Parenteral formulation unspecified;Protein recombinant;Monoclonal antibody humanized
Last Change Date	20-Sep-2014

### undisclosed mAb biosimilar (cancer), Pfenex/Stelis DEVELOPMENT PROFILE

#### SUMMARY

Pfenex/Stelis (following Agila's name change), an unnamed joint venture created by Pfenex and Stelis (formerly Agila Biotech (Agila Specialties)), following the acquisition of Inbiopro, is investigating IBPM-002BZ, a humanized anti-Her-2/neu mAb and a biosimilar version of an undisclosed drug, for the potential treatment of cancer including metastatic colorectal cancer, small cell lung cancer and metastatic renal cell carcinoma ,,. In 2010, process development and toxicology studies had begun ; in 2012, development was ongoing . In January 2014, IBPM-002BZ was listed on the Inbiopro's company pipeline.

### undisclosed mAb biosimilar (cancer), Pfenex/Stelis DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Pfenex/Stelis Joint Venture	Cancer	India	Discovery	16-Apr-2013
Inbiopro Solutions Pvt Ltd	Cancer	India	Discontinued	09-Dec-2010

[Return to Table of Contents](#)



undisclosed mAb biosimilar (cancer), Pfenex/Stelis DRUG NAMES

Names	Type
undisclosed mAb biosimilar (cancer), Pfenex/Stelis	
IBPM-002BZ	Research Code
undisclosed mAb biosimilar (cancer), Inbiopro	
undisclosed mAb biosimilar (cancer), Stelis	
undisclosed mAb biosimilar (cancer), Agila	

[Return to Table of Contents](#)

## undisclosed mAb biosimilar (non-Hodgkin's lymphoma/rheumatoid arthritis), Pfenex/Stelis

### undisclosed mAb biosimilar (non-Hodgkin's lymphoma/rheumatoid arthritis), Pfenex/Stelis SNAPSHOT

<b>Drug Name</b>	undisclosed mAb biosimilar (non-Hodgkin's lymphoma/rheumatoid arthritis), Pfenex/Stelis
<b>Key Synonyms</b>	
<b>Originator Company</b>	Inbiopro Solutions Pvt Ltd
<b>Active Companies</b>	Pfenex/Stelis Joint Venture
<b>Inactive Companies</b>	Inbiopro Solutions Pvt Ltd;Stelis Biopharma Pvt Ltd
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Rheumatoid arthritis;Non-Hodgkin lymphoma
<b>Target-based Actions</b>	B-lymphocyte antigen CD20 inhibitor
<b>Other Actions</b>	Anticancer monoclonal antibody;Anti-inflammatory
<b>Technologies</b>	Biosimilar product;Biological therapeutic;Parenteral formulation unspecified;Protein recombinant;Chimeric monoclonal antibody
<b>Last Change Date</b>	20-Sep-2014

### undisclosed mAb biosimilar (non-Hodgkin's lymphoma/rheumatoid arthritis), Pfenex/Stelis DEVELOPMENT PROFILE

#### SUMMARY

Pfenex/Stelis (following Agila's name change), an unnamed joint venture created by Pfenex and Stelis (formerly Agila Biotech (Agila Specialties)), following the acquisition of Inbiopro, is investigating IBPM-001RX, a chimeric IgG1 kappa mAb targeting CD20 antigen and a biosimilar version of an undisclosed drug, for the potential treatment of non-Hodgkin's lymphoma and rheumatoid arthritis,. By 2010, process development and toxicology studies had been completed . In August 2012, the drug was listed on Inbiopro's development pipeline ; in January 2014, this was still the case.

### undisclosed mAb biosimilar (non-Hodgkin's lymphoma/rheumatoid arthritis), Pfenex/Stelis DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Pfenex/Stelis Joint Venture	Non-Hodgkin lymphoma	India	Discovery	16-Apr-2013
Pfenex/Stelis Joint Venture	Rheumatoid arthritis	India	Discovery	16-Apr-2013
Inbiopro Solutions Pvt Ltd	Non-Hodgkin lymphoma	India	Discontinued	09-Dec-2010
Inbiopro Solutions Pvt Ltd	Rheumatoid arthritis	India	Discontinued	09-Dec-2010

[Return to Table of Contents](#)

undisclosed mAb biosimilar (non-Hodgkin's lymphoma/rheumatoid arthritis), Pfenex/Stelis DRUG NAMES

Names	Type
IBPM-001RX	Research Code
undisclosed mAb biosimilar (non-Hodgkin's lymphoma/rheumatoid arthritis), Agila	
undisclosed mAb biosimilar (non-Hodgkin's lymphoma/rheumatoid arthritis), Inbiopro	
undisclosed mAb biosimilar (non-Hodgkin's lymphoma/rheumatoid arthritis), Pfenex/Stelis	
undisclosed mAb biosimilar (non-Hodgkin's lymphoma/rheumatoid arthritis), Stelis	

[Return to Table of Contents](#)

## undisclosed mAb biosimilar (inflammatory diseases), Pfenex/Stelis

### undisclosed mAb biosimilar (inflammatory diseases), Pfenex/Stelis SNAPSHOT

<b>Drug Name</b>	undisclosed mAb biosimilar (inflammatory diseases), Pfenex/Stelis
<b>Key Synonyms</b>	
<b>Originator Company</b>	Inbiopro Solutions Pvt Ltd
<b>Active Companies</b>	Pfenex/Stelis Joint Venture
<b>Inactive Companies</b>	Inbiopro Solutions Pvt Ltd;Stelis Biopharma Pvt Ltd
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Inflammatory disease
<b>Target-based Actions</b>	TNF antagonist
<b>Other Actions</b>	Anti-inflammatory
<b>Technologies</b>	Biosimilar product;Biological therapeutic;Parenteral formulation unspecified;Protein recombinant;Monoclonal antibody human
<b>Last Change Date</b>	20-Sep-2014

### undisclosed mAb biosimilar (inflammatory diseases), Pfenex/Stelis DEVELOPMENT PROFILE

#### SUMMARY

Pfenex/Stelis (following Agila's name change), an unnamed joint venture created by Pfenex and Stelis (formerly Agila Biotech (Agila Specialties)), following the acquisition of Inbiopro, is investigating IBPM-004AM, a fully human mAb targeting TNF and a biosimilar version of an undisclosed drug, for the potential treatment of inflammatory diseases including rheumatoid arthritis, juvenile arthritis, ankylosing spondylitis, Crohn's disease and psoriatic arthritis,,. In 2010, process development and toxicology studies had begun. In January 2014, IBPM-004AM was listed on the Inbiopro company's pipeline.

### undisclosed mAb biosimilar (inflammatory diseases), Pfenex/Stelis DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Pfenex/Stelis Joint Venture	Inflammatory disease	India	Discovery	16-Apr-2013
Inbiopro Solutions Pvt Ltd	Inflammatory disease	India	Discontinued	09-Dec-2010

[Return to Table of Contents](#)





undisclosed mAb biosimilar (inflammatory diseases), Pfenex/Stelis DRUG NAMES

Names	Type
undisclosed mAb biosimilar (inflammatory diseases), Stelis	
undisclosed mAb biosimilar (inflammatory diseases), Agila	
undisclosed mAb biosimilar (inflammatory diseases), Pfenex/Stelis	
undisclosed mAb biosimilar (inflammatory diseases), Inbiopro	
IBPM-004AM	Research Code

## undisclosed chimeric mAb biosimilar (inflammatory diseases), Pfenex/Stelis

### undisclosed chimeric mAb biosimilar (inflammatory diseases), Pfenex/Stelis SNAPSHOT

<b>Drug Name</b>	undisclosed chimeric mAb biosimilar (inflammatory diseases), Pfenex/Stelis
<b>Key Synonyms</b>	
<b>Originator Company</b>	Inbiopro Solutions Pvt Ltd
<b>Active Companies</b>	Pfenex/Stelis Joint Venture
<b>Inactive Companies</b>	Inbiopro Solutions Pvt Ltd;Stelis Biopharma Pvt Ltd
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Inflammatory disease
<b>Target-based Actions</b>	TNF alpha ligand inhibitor
<b>Other Actions</b>	Anti-inflammatory
<b>Technologies</b>	Biosimilar product;Biological therapeutic;Parenteral formulation unspecified;Protein recombinant;Chimeric monoclonal antibody
<b>Last Change Date</b>	20-Sep-2014

### undisclosed chimeric mAb biosimilar (inflammatory diseases), Pfenex/Stelis DEVELOPMENT PROFILE

#### SUMMARY

Pfenex/Stelis (following Agila's name change), an unnamed joint venture created by Pfenex and Stelis (formerly Agila Biotech (Agila Specialties)), following the acquisition of Inbiopro, is investigating IBPM-005IX, a chimeric mAb targeting TNF-alpha and a biosimilar version of an undisclosed drug, for the potential treatment of inflammatory diseases including rheumatoid arthritis, juvenile arthritis, ankylosing spondylitis, Crohn's disease and psoriatic arthritis,. In 2011, process development and toxicology studies had begun. In January 2014, IBPM-005IX was listed on the Inbiopro company's pipeline.

### undisclosed chimeric mAb biosimilar (inflammatory diseases), Pfenex/Stelis DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Pfenex/Stelis Joint Venture	Inflammatory disease	India	Discovery	16-Apr-2013
Inbiopro Solutions Pvt Ltd	Inflammatory disease	India	Discontinued	09-Dec-2010

[Return to Table of Contents](#)



undisclosed chimeric mAb biosimilar (inflammatory diseases), Pfenex/Stelis DRUG NAMES

Names	Type
undisclosed chimeric mAb biosimilar (inflammatory diseases), Agila	
IBPM-005IX	Research Code
undisclosed chimeric mAb biosimilar (inflammatory diseases), Pfenex/Stelis	
undisclosed chimeric mAb biosimilar (inflammatory diseases), Stelis	
undisclosed chimeric mAb biosimilar (inflammatory diseases), Inbiopro	

## IFN alpha 2b biosimilar, Pfenex

### IFN alpha 2b biosimilar, Pfenex SNAPSHOT

Drug Name	IFN alpha 2b biosimilar, Pfenex
Key Synonyms	interferon alfa-2b
Originator Company	Pfenex Inc
Active Companies	Pfenex Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Inflammatory disease
Target-based Actions	Interferon alpha 2 ligand modulator
Other Actions	Anti-inflammatory
Technologies	Biosimilar product;Biological therapeutic;Protein recombinant
Last Change Date	24-Jul-2014

### IFN alpha 2b biosimilar, Pfenex DEVELOPMENT PROFILE

#### SUMMARY

Pfenex is investigating a biosimilar version of IFN alpha 2b for the potential treatment of inflammatory diseases. By February 2013, investigations were ongoing.

### IFN alpha 2b biosimilar, Pfenex DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Pfenex Inc	Inflammatory disease	US	Discovery	26-Feb-2013

### IFN alpha 2b biosimilar, Pfenex DRUG NAMES

Names	Type
interferon alfa-2b	INN, USAN
IFN alpha 2b biosimilar, Pfenex	

[Return to Table of Contents](#)

## PF-688

### PF-688 SNAPSHOT

Drug Name	PF-688
Key Synonyms	certolizumab pegol
Originator Company	Pfenex Inc
Active Companies	Pfenex Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Inflammatory disease
Target-based Actions	TNF antagonist;TNF alpha ligand inhibitor
Other Actions	Anti-inflammatory;TNF binding agent
Technologies	Biosimilar product;Injectable formulation;PEGylated formulation;Biological therapeutic;Parenteral formulation unspecified;Protein recombinant;Monoclonal antibody humanized;Antibody fragment
Last Change Date	04-Dec-2013

### PF-688 DEVELOPMENT PROFILE

#### SUMMARY

Pfenex is investigating PF-688, a biosimilar version of certolizumab pegol, an anti-TNF-alpha humanized monoclonal antibody fragment, as an injectable formulation, for the potential use in the treatment of inflammatory diseases including Crohn's disease. In November 2013, the biosimilar was listed as being in preclinical development and at that time, the company was seeking to outlicense the biosimilar.

### PF-688 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Pfenex Inc	Inflammatory disease	US	Discovery	26-Mar-2013

### PF-688 DRUG NAMES

Names	Type
certolizumab pegol	INN
certolizumab pegol biosimilar, Pfenex	
PF-688	Research Code

[Return to Table of Contents](#)





## PRIMALVAC

### PRIMALVAC SNAPSHOT

Drug Name	PRIMALVAC
Key Synonyms	
Originator Company	European Vaccine Initiative
Active Companies	INSERM;European Vaccine Initiative;Pfenex Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Plasmodium infection
Target-based Actions	
Other Actions	Prophylactic vaccine;Protein subunit vaccine
Technologies	Biological therapeutic;Protein recombinant
Last Change Date	20-Feb-2015

### PRIMALVAC DEVELOPMENT PROFILE

#### SUMMARY

European Vaccine Initiative, INSERM and Pfenex are investigating PRIMALVAC, a vaccine comprised of var2 chondroitin sulfate A (var2CSA), for the potential prevention of pregnancy related malaria. In February 2015, a phase I trial was in preparation and was expected to be initiated in 2015.

### PRIMALVAC DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
European Vaccine Initiative	Plasmodium infection	Germany	Discovery	30-Sep-2011
INSERM	Plasmodium infection	France	Discovery	30-Sep-2011
Pfenex Inc	Plasmodium infection	US	Discovery	30-Sep-2011

### PRIMALVAC DRUG NAMES

Names	Type
PRIMALVAC	

[Return to Table of Contents](#)







## peginterferon beta 1b, Pfenex

### peginterferon beta 1b, Pfenex SNAPSHOT

Drug Name	peginterferon beta 1b, Pfenex
Key Synonyms	
Originator Company	Pfenex/Stelis Joint Venture
Active Companies	Pfenex Inc
Inactive Companies	Pfenex/Stelis Joint Venture
Highest Status	Discovery
Active Indications	Unidentified indication
Target-based Actions	Interferon beta ligand
Other Actions	
Technologies	PEGylated formulation;Biological therapeutic;Parenteral formulation unspecified;Protein recombinant
Last Change Date	18-Mar-2015

### peginterferon beta 1b, Pfenex DEVELOPMENT PROFILE

#### SUMMARY

Pfenex (following the removal of program from Joint Development and License Agreement) is investigating peginterferon beta 1b (PF-726), for the potential treatment of undisclosed indication. In March 2015, development was ongoing.

Pfenex/Stelis Joint Venture, an unnamed joint venture created by Pfenex and Stelis was previously investigating peginterferon beta 1b, for the potential treatment of undisclosed indication. However, in March 2015, the program was removed from the Joint Development and License Agreement.

### peginterferon beta 1b, Pfenex DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Pfenex Inc	Unidentified indication	Malaysia	Discovery	16-Mar-2015
Pfenex/Stelis Joint Venture	Unidentified indication	Malaysia	Discontinued	16-Mar-2015

[Return to Table of Contents](#)



peginterferon beta 1b, Pfenex DRUG NAMES

Names	Type
peginterferon beta 1B	
peginterferon beta 1b, Pfenex	
PF-726	Research Code

[Return to Table of Contents](#)

## rPA vaccine (solid-dose injectable/ Glide SDI, anthrax), Pfenex / Glide

### rPA vaccine (solid-dose injectable/ Glide SDI, anthrax), Pfenex / Glide SNAPSHOT

Drug Name	rPA vaccine (solid-dose injectable/ Glide SDI, anthrax), Pfenex / Glide
Key Synonyms	
Originator Company	Pfenex Inc
Active Companies	Pfenex Inc;Glide Pharmaceutical Technologies Ltd
Inactive Companies	
Highest Status	Discovery
Active Indications	Bacillus anthracis infection
Target-based Actions	
Other Actions	Recombinant bacterial vector vaccine;Antibacterial
Technologies	Injectable controlled release formulation;Antigen;Biological therapeutic;Parenteral formulation unspecified;Formulation solid
Last Change Date	10-Mar-2015

### rPA vaccine (solid-dose injectable/ Glide SDI, anthrax), Pfenex / Glide DEVELOPMENT PROFILE

#### SUMMARY

Pfenex and Glide Pharma are investigating a solid dose formulation of Pfenex's recombinant protective antigen (rPA) vaccine, using Pfenex's Expression technology (a Pseudomonas fluorescence-based platform technology) and Glide's Glide SDI solid dose injector technology, for the potential prevention or treatment of anthrax infection. By March 2015, "encouraging" stability data had been observed with initial formulations of the vaccine.

### rPA vaccine (solid-dose injectable/ Glide SDI, anthrax), Pfenex / Glide DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Glide Pharmaceutical Technologies Ltd	Bacillus anthracis infection	UK	Discovery	30-Apr-2013
Pfenex Inc	Bacillus anthracis infection	US	Discovery	30-Apr-2013

[Return to Table of Contents](#)




rPA vaccine (solid-dose injectable/ Glide SDI, anthrax), Pfenex / Glide DRUG NAMES

Names	Type
recombinant protective antigen vaccine (solid, anthrax infection), Pfenex / Glide	
rPA vaccine (solid, anthrax), Pfenex / Glide	
rPA vaccine (solid-dose injectable/ Glide SDI, anthrax), Pfenex / Glide	

rPA vaccine (solid-dose injectable/ Glide SDI, anthrax), Pfenex / Glide DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Glide Pharmaceutical Technologies Ltd	1	0	0	0	1
Pfenex Inc	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	0	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

